ZIA CP010131-10741 (ZIA) | |||
---|---|---|---|
Title | Second cancers after bone marrow transplantation | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Morton, Lindsay | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $50,855 | Project Dates | 00/00/0000 - 00/00/0000 |
Fiscal Year | 2017 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Biochemical Epidemiology (45.0%) Cancer (100.0%) Cancer Survivorship (75.0%) Chemotherapy (75.0%) Childhood Cancers (25.0%) |
N/A | ||
Research Type | |||
Exogenous Factors in the Origin and Cause of Cancer Patient Care and Survivorship Issues |
|||
Abstract | |||
"""Allogeneic BMT is a potentially curative treatment for cancer (e.g., hematologic) and non-cancer (e.g., sickle cell) diseases. However, survivors are prone to a unique set of complications and late effects that reflect the complex interplay between their primary disease, prior treatments, conditioning therapy, and graft versus host disease (GVHD). Understanding the onset and course of late effects is important in order to provide timely screening and interventions as an attempt to reduce the risk of late effects and related morbidity and mortality after BMT. In particular, new malignancies are an important cause of morbidity and mortality after BMT. Studies will be conducted in collaboration with the Center for International Blood & Marrow Transplant Research (CIBMTR) to quantify risks for new malignancies and identify specific risk factors.""" |